Are peptides legal? Which peptides a compounding pharmacy can make in 2026

Some peptides are FDA-approved drugs, such as insulin, and are legal with a prescription like any other prescription drug. Peptides that are not FDA-approved can reach patients legally only one way: a licensed pharmacy compounds them on a prescription, from an ingredient the law allows it to use. In 2026 the rules for several popular peptides changed. Six of them, BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, are now covered by a federal enforcement discretion policy released on October 28, 2026, which sets strict conditions on how they are sourced, labeled and compounded. None of them is FDA-approved, and peptides sold as "research use only" are not drugs for people.

This page explains what a compounding pharmacy is allowed to do with peptides, what changed in 2026, and how to tell whether a compounded peptide was made within the rules. Peptide regulation is moving quickly, so we update this page as federal policy changes. It reflects federal policy as of November 11, 2026.

Which peptides can a compounding pharmacy use?

A 503A compounding pharmacy prepares medications for one named patient on a prescription. Under section 503A of the Federal Food, Drug, and Cosmetic Act, it may compound from a bulk drug substance only if that substance meets one of three conditions:

• It complies with an applicable USP or National Formulary monograph.
• It is a component of an FDA-approved drug product.
• It appears on FDA's 503A bulks list.

In every case the substance must come with a valid certificate of analysis and be made by an establishment registered with FDA. Most peptides people ask about meet none of the three conditions, which is why their status depends on FDA's interim policies. Our guide to 503A and 503B pharmacies explains the 503A category in more detail.

What are FDA's Category 1 and Category 2 lists?

While FDA evaluates substances nominated for the 503A bulks list, it sorts many of them into interim categories:

• Category 1: substances FDA does not intend to take action against while it decides whether to add them to the bulks list, provided its conditions are met. As of FDA's May 14, 2026 list, the peptides in Category 1 are GHK-Cu (non-injectable routes only), glutathione, vasoactive intestinal peptide and alanyl-L-glutamine.
• Category 2: substances FDA has identified as raising significant safety risks. As of the same list, the one peptide in Category 2 is kisspeptin-10.
• Category 3: substances nominated without enough supporting information.

A peptide that sits in none of these categories, and meets none of the three conditions above, is not eligible for 503A compounding under FDA's interim bulks policy. The six peptides in the HHS policy below are the current exception.

What changed for peptides in 2026?

• 2023: FDA placed 19 peptide or peptide-related bulk drug substances in Category 2, which effectively stopped pharmacies from compounding them.
• April 2026: FDA removed 12 peptides from Category 2, citing withdrawal of the nominations. Removal did not, on its own, make them eligible for compounding.
• July 23 and 24, 2026: FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list and voted, narrowly, to recommend six of them: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It did not recommend emideltide. FDA staff had recommended against all seven. Advisory committee votes are recommendations and do not change the list on their own.
• October 28, 2026: the Department of Health and Human Services released an enforcement discretion policy covering the six recommended peptides, published in the Federal Register on October 30, 2026 as a draft open for public comment.

Which six peptides does the HHS policy cover?

The policy applies only to specific forms of each peptide, and only by the routes of administration HHS listed for it:

A product outside those forms and routes is not covered, even if it contains one of the six peptides.

What conditions does the HHS policy set?

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding one of the six peptides when all of these conditions are met:

• The peptide is on the policy's list, with the identity and route limits HHS set for it.
• The bulk peptide comes from an FDA-registered facility, with a valid certificate of analysis showing identity, purity, potency and absence of harmful contaminants.
• The original manufacturer, not only a repackager or distributor, is FDA-registered, follows current good manufacturing practice, and is named on the certificate of analysis.
• The compounder reports serious adverse events and quality problems to FDA's MedWatch program and to the relevant states.
• The label states: "This is a compounded drug product. Not for resale."
• The product contains only one of the listed peptides as its active ingredient.
• For oral products, the compounder has documentation that the formulation is adequately absorbed in humans.
• The only delivery device packaged with the product is an FDA-cleared syringe.
• The product meets the other requirements of federal law, including a prescription for an individual patient and compounding under sanitary conditions.

What the policy does not do

• It does not approve any peptide. Compounded peptides are not FDA-approved.
• It does not add any peptide to the 503A bulks list. That still requires FDA rulemaking.
• It is interim. It applies until each peptide is addressed in a final rule, and HHS says it may revisit the policy if a safety signal or product quality problem arises.
• It does not remove the prescription requirement.
• It covers federal enforcement only. State boards of pharmacy set their own rules.

What about "research use only" peptides?

Peptides sold online as "research use only" or "not for human consumption" are not prescription drugs and are not compounded for a named patient. HHS states that one purpose of its policy is to discourage the widespread use of research-use-only peptides supplied by foreign manufacturers, and to offer compounding under the policy's safeguards as a more controlled alternative.

How to tell if a compounded peptide was made within the rules

• It was dispensed on a prescription written for you by a licensed prescriber.
• It came from a state-licensed pharmacy, licensed in your state if it was shipped to you.
• For the six peptides in the HHS policy, the label reads "This is a compounded drug product. Not for resale.", the product has a single active peptide, and it matches one of the routes in the table above.
• The pharmacy can tell you where the bulk peptide came from and whether it holds a certificate of analysis from the original manufacturer.

What this means for you

Whether a peptide is appropriate for you is your prescriber's decision. If you are considering one, ask your prescriber about the evidence for your situation, and ask the pharmacy how the peptide is sourced and labeled. For a broader look at how compounding pharmacies are licensed and held to standards, read are compounding pharmacies safe, or start with what a compounding pharmacy is.